Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…Abstract Number: 1686 • ACR Convergence 2021
Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy
Background/Purpose: Olokizumab (OKZ), a humanized monoclonal antibody targeting IL-6, was studied in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) (NCT02760368, NCT02760407) [1]. Here…Abstract Number: 1702 • ACR Convergence 2021
Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib, an oral selective inhibitor of Janus kinase (JAK) 1 and 2, improved signs and symptoms of rheumatoid arthritis(RA).We analyze efficacy and safety of…Abstract Number: 1912 • ACR Convergence 2021
Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Background/Purpose: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. We aimed to…Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…Abstract Number: 0014 • ACR Convergence 2021
Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which is characterized by erosive arthritis and systemic inflammation. Tofacitinib (TFCN) is a Janus…Abstract Number: 0032 • ACR Convergence 2021
IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…Abstract Number: 0096 • ACR Convergence 2021
The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study
Background/Purpose: Observational data have shown that rheumatic patients seem not to be more susceptible to SARS-CoV-2 infection neither to worse outcomes. However, the true prevalence…Abstract Number: 0170 • ACR Convergence 2021
Direct and Conditional Effects of Epicardial Adipose Tissue Volume on Coronary Plaque Progression in Rheumatoid Arthritis
Background/Purpose: Epicardial adipose tissue volume (EATv) predicts coronary atherosclerosis presence, progression and cardiovascular events in general patients. We recently reported that EATv associated with greater…Abstract Number: 0271 • ACR Convergence 2021
Higher Prevalence of Subclinical Atherosclerosis in the First Five Years of Rheumatoid Arthritis Diagnosis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of developing a cardiovascular (CV) event than the general population, due to an accelerated process…Abstract Number: 0288 • ACR Convergence 2021
Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…Abstract Number: 0462 • ACR Convergence 2021
Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Background/Purpose: Inflammatory rheumatic disease (IRD) related fatigue is pervasive and disabling, even in otherwise stable disease. Although cognitive-behavioural approaches (CBAs) and personalised exercise programmes (PEP)…Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…Abstract Number: 0590 • ACR Convergence 2021
Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population
Background/Purpose: Lipid mediators are endogenously derived from the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and have important roles in promoting and resolving…Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 188
- Next Page »